We are live on ! Find out more
NVO icon

Novo Nordisk

1,863 hedge funds and large institutions have $47.8B invested in Novo Nordisk in 2024 Q2 according to their latest regulatory filings, with 186 funds opening new positions, 765 increasing their positions, 589 reducing their positions, and 80 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 186 | Existing positions closed: 80

65% more capital inflows, than outflows

Capital inflows: $3.41B | Capital outflows: $2.07B

30% more repeat investments, than reductions

Existing positions increased: 765 | Existing positions reduced: 589

14% more funds holding in top 10

Funds holding in top 10: 80 → 91 (+11)

7% more funds holding

Funds holding: 1,743 → 1,863 (+120)

0.25% more ownership

Funds ownership: 7.27% → 7.51% (+0.25%)

4% less call options, than puts

Call options by funds: $1.09B | Put options by funds: $1.13B

Holders
1,863
Holders Change
+120
Holders Change %
+6.88%
% of All Funds
26.83%
Holding in Top 10
91
Holding in Top 10 Change
+11
Holding in Top 10 Change %
+13.75%
% of All Funds
1.31%
New
186
Increased
765
Reduced
589
Closed
80
Calls
$1.09​B
Puts
$1.13​B
Net Calls
-⁠$42.5​M
Net Calls Change
+$73.9​M

NVO Hedge Fund Activity: Q2 2024 in Review

1,863 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2024, worth a combined $47.8B — up 15% from $41.7B a quarter earlier.

Buyers outnumbered sellers: 186 funds opened new NVO positions and 80 closed out — a net gain of 106 holders — while 765 added to existing stakes and 589 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $344M. The largest seller was Renaissance Technologies, cutting an estimated $215M.

  • 1,863 institutional investors held Novo Nordisk (NVO) as of Q2 2024, up from 1,743 in Q1 2024.
  • Funds reported $47.8B of Novo Nordisk stock for Q2 2024, up 15% quarter-over-quarter.
  • 186 funds opened new Novo Nordisk positions in Q2 2024 and 80 closed out, a net change of +106 holders.
  • The largest Novo Nordisk buyer in Q2 2024 was Morgan Stanley, an estimated $344M added.
  • The largest Novo Nordisk seller in Q2 2024 was Renaissance Technologies, an estimated $215M sold.

Based on aggregated 13F filings for Q2 2024.